Details for New Drug Application (NDA): 010379
✉ Email this page to a colleague
NDA 010379 describes CYTOMEL, which is a drug marketed by King Pharms and is included in one NDA. It is available from two suppliers. Additional details are available on the CYTOMEL profile page.
The generic ingredient in CYTOMEL is liothyronine sodium. There are four drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the liothyronine sodium profile page.
The generic ingredient in CYTOMEL is liothyronine sodium. There are four drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the liothyronine sodium profile page.
Summary for 010379
| Tradename: | CYTOMEL |
| Applicant: | King Pharms |
| Ingredient: | liothyronine sodium |
| Patents: | 0 |
Suppliers and Packaging for NDA: 010379
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CYTOMEL | liothyronine sodium | TABLET;ORAL | 010379 | NDA AUTHORIZED GENERIC | Mylan Pharmaceuticals Inc. | 59762-1206 | 59762-1206-1 | 100 TABLET in 1 BOTTLE (59762-1206-1) |
| CYTOMEL | liothyronine sodium | TABLET;ORAL | 010379 | NDA AUTHORIZED GENERIC | Mylan Pharmaceuticals Inc. | 59762-1207 | 59762-1207-1 | 100 TABLET in 1 BOTTLE (59762-1207-1) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 0.005MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | AB | RLD: | Yes | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 0.025MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | AB | RLD: | Yes | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 0.05MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | AB | RLD: | Yes | ||||
Complete Access Available with Subscription
